Oncology Team Geneva shared a post on LinkedIn about a recent article by Hiba Mechahougui et al, published in Clinical Cancer Research:
“How can we help the immune system better recognize and destroy cancer cells?
In a recent publication, Prof. Alfredo Addeo highlights the power of immune checkpoint inhibitors (ICIs) and outlines the most promising directions for the future of cancer treatment.
Immune checkpoint inhibitors work by ‘releasing the brakes’ of the immune system, enabling T cells to better identify and attack tumor cells. This comprehensive review brings together biological mechanisms and the latest clinical evidence in immuno-oncology.
Key takeaways from the paper:
- ICIs targeting PD-1/PD-L1 and CTLA-4 show meaningful clinical benefits, including improved survival and objective response across multiple cancer types.
- Viral infections may influence antitumor immune responses, and some virus-associated tumors could be particularly sensitive to immunotherapy.
- The authors emphasize the importance of biomarkers to better select patients and the development of combination strategies to optimize treatment outcomes in heterogeneous populations.
Why it matters:
Immunotherapy is already transforming cancer care, but its full potential lies in a more personalized, biomarker-driven approach.”
Title: Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors Open Access
Authors: Hiba Mechahougui, Léna Royston, Catia Vieira Gomes, Laurent Kaiser, Thibaud Koessler, Timothée Olivier, Nicolas Mach, S. Intidhar Labidi-Galy, Kaushal Parikh, Alfredo Addeo
Read the Full Article on Clinical Cancer Research
More posts about Immune Checkpoint Inhibitors.